Alentis Therapeutics Competitors and Similar CompaniesClear all
Alentis Therapeutics's competitors and similar companies include EyePoint Pharmaceuticals, Sol-Gel Technologies, STADA and Faes Farma.
 Alentis Therapeutics Alentis Therapeutics is a company that discovers and develops medications to treat liver diseases. |  EyePoint Pharmaceuticals EyePoint Pharmaceuticals (formerly pSivida) is a pharmaceutical company focused on the development of innovative miniaturized, sustained-release drug delivery products and technologies to treat serious, debilitating diseases of the eye that can lead to blindness. |  Sol-Gel Technologies Sol-Gel Technologies is engaged in the development of a range of specialty pharmaceuticals. |  Faes Farma Faes Farma is a pharmaceutical company that develops, produces and commercializes pharmaceutical products and raw materials. | ||
Founding Date | Founding Date 1993 | Founding Date 1987 | Founding Date 1997 | Founding Date 1895 | Founding Date 1933 |
Type | Type Private | Type Public | Type Public | Type Public | Type Public |
Tags | |||||
Locations | Locations Basel, CH HQ | Locations Watertown, US HQ | Locations Ness Ziona, IL HQ | Locations Bad Vilbel, DE HQ Beijing, CN Hangzhou Shi, CN Shanghai, CN Bad Vilbel, DE Budapest, HU Vilnius, LT see more | Locations Leioa, ES HQ Madrid, ES Atlanta, US |
Employees | Employees N/A | Employees 8453% increase | Employees 34 | Employees 12,33911% increase | Employees 1,775 |
Valuation ($) | Valuation ($) N/A | Valuation ($) 617.6 m | Valuation ($) 18 m | Valuation ($) 6 b | Valuation ($) 1.2 b |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) $31.4m (FY, 2025) | Revenue (est.) $19.4m (FY, 2025) | Revenue (est.) €3b (FY, 2020) | Revenue (est.) €493.6m (FY, 2024) |
Cost of goods | Cost of goods N/A | Cost of goods N/A | Cost of goods N/A | Cost of goods €1.3b (FY, 2020) | Cost of goods €167.1m (FY, 2024) |
Gross profit | Gross profit N/A | Gross profit N/A | Gross profit $19.4m (FY, 2025) | Gross profit €1.7b (FY, 2020) | Gross profit €342.9m (FY, 2024) |
Net income | Net income N/A | Net income ($232m) (FY, 2025) | Net income ($6.1m) (FY, 2025) | Net income €181.9m (FY, 2020) | Net income €111.1m (FY, 2024) |
Funding | |||||
Total funding raised | Total funding raised $ 95.3m | Total funding raised $ 40m | Total funding raised N/A | Total funding raised N/A | Total funding raised N/A |
For sources of this data, please see the company profile
View Company Profiles
EyePoint Pharmaceuticals
HQ
Watertown, US
Employees
84
EyePoint Pharmaceuticals (formerly pSivida) is a pharmaceutical company focused on the development of innovative miniaturized, sustained-release drug delivery products and technologies to treat serious, debilitating diseases of the eye that can lead to blindness.
View companySol-Gel Technologies
HQ
Ness Ziona, IL
Employees
34
Sol-Gel Technologies is engaged in the development of a range of specialty pharmaceuticals.
View company
STADA
HQ
Bad Vilbel, DE
Employees
12,339↑ 11% increase
STADA Arzneimittel is a company engaged in the healthcare and pharmaceuticals business.
View companyFaes Farma
HQ
Leioa, ES
Employees
1,775
Faes Farma is a pharmaceutical company that develops, produces and commercializes pharmaceutical products and raw materials.
View company